Serum Asymmetric Dimethylarginine Levels in Patients with Acute Rheumatic Fever

Basit Öğe Kaydı
dc.contributor.authorSert, Ahmet
dc.contributor.authorCimen, Derya
dc.contributor.authorArslan, Derya
dc.contributor.authorAypar, Ebru
dc.contributor.authorVatansev, Husamettin
dc.contributor.authorKaya, Fatma
dc.contributor.authorKilicaslan, Cengizhan
dc.date.accessioned2020-03-26T19:07:02Z
dc.date.available2020-03-26T19:07:02Z
dc.date.issued2015
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAsymmetric dimethylarginine (ADMA) is an analogue of L-arginine, a naturally occurring product of metabolism found in human circulation. It is an endogenous inhibitor of nitric oxide production. Acute rheumatic fever (ARF) is a delayed immunologically mediated autoimmune sequel of throat infection by group A beta-hemolytic streptococci. As serum ADMA levels have not previously been assessed in patients with ARF, we aimed to investigate ADMA levels in patients with ARF during the acute stage and after anti-inflammatory treatment and compared results with healthy control subjects. The study population consisted of 34 children with ARF (30 patients with carditis and 4 patients without carditis) and 31 healthy control subjects. Erythrocyte sedimentation rate and C-reactive protein values were significantly higher and serum ADMA values were lower, but not statistically significant in patients with ARF during the acute stage when compared with controls. Serum C-reactive protein and erythrocyte sedimentation rate values were significantly decreased in patients with ARF after the treatment when compared with baseline and ADMA levels were increased after the treatment compared with baseline, but this change was not statistically significant. Our study has demonstrated that resolution of acute inflammation in patients with ARF may lead to a mild increase in serum concentration of ADMA. Comprehensive prospective and observational studies are required to confirm our findings and to assess potential interactions between ARF and ADMA levels.en_US
dc.identifier.doi10.1055/s-0035-1554781en_US
dc.identifier.endpage27en_US
dc.identifier.issn1879-5390en_US
dc.identifier.issn1879-5404en_US
dc.identifier.issue1en_US
dc.identifier.pmid#YOKen_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage21en_US
dc.identifier.urihttps://dx.doi.org/10.1055/s-0035-1554781
dc.identifier.urihttps://hdl.handle.net/20.500.12395/32539
dc.identifier.volume5en_US
dc.identifier.wosWOS:000219000300006en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherGEORG THIEME VERLAG KGen_US
dc.relation.ispartofJOURNAL OF PEDIATRIC BIOCHEMISTRYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectacute rheumatic feveren_US
dc.subjectasymmetric dimethylarginineen_US
dc.subjectcarditisen_US
dc.titleSerum Asymmetric Dimethylarginine Levels in Patients with Acute Rheumatic Feveren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu